People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology, Pharmaceuticals, Other, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dren Bio, Inc. | — | Biotechnology | Series C | $93.1M | $1.3B | 2020 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2020 |
| ARS Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $63.0M | $1.3B | 2021 |
| IlluminOss Medical Inc | — | Other | Series B | $39.9M | $83.0M | 2014 |
| Synovex Corp | — | Other Technology | Seed | $3.5M | $119.3M | 2012 |
| Adheron Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.5M | $57.1M | 2015 |
| Avhana Health, Inc. | — | Other Health Care | Pre-Seed | $676K | $20.8M | 2015 |
Rajeev Dadoo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rajeev Dadoo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ron Laufer | 2 | 3 |
| Isai Peimer | 2 | 2 |
| Doug Onsi | 2 | 2 |
| Jean-Francois Formela | 1 | 17 |
| Kevin Bitterman | 1 | 15 |
| Jonathan Leff | 1 | 11 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Peter Kolchinsky | 1 | 8 |
| Fouad Azzam | 1 | 8 |
| Alex Kolicich | 1 | 8 |
| Sakae Asanuma | 1 | 6 |
| Enrico Petrillo | 1 | 6 |
| Christopher Mirabelli | 1 | 6 |
| Brent Saunders | 1 | 5 |
| Paul Friedman | 1 | 5 |
| Lee Wrubel | 1 | 5 |
| Pratik Shah | 1 | 5 |
| John Creecy | 1 | 5 |
| THOMAS HUGHES | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.